Pityriasis lichenoides chronica (PLC); Papulovesicular; generalized eruption, a rash all over her body; pruritis; pain; It was extremely uncomfortable with sleepless nights; This is a spontaneous report received from contactable reporter(s) (Physician) from medical information team.  A 33 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm, administration date 10Apr2021 (Batch/Lot number: unknown) at the age of 33 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose: 1st, Anatomical site of injection: Arm , Route: IM), administration date: Mar2021, for Covid-19 immunization, reaction(s): "No reaction on previous exposure to vaccine". The following information was reported: RASH (non-serious) with onset 24Apr2021, outcome "recovering", described as "generalized eruption, a rash all over her body"; INSOMNIA (non-serious) with onset 2021, outcome "unknown", described as "It was extremely uncomfortable with sleepless nights"; RASH PRURITIC (non-serious) with onset 24Apr2021, outcome "unknown", described as "pruritis"; PAIN (non-serious) with onset 2021, outcome "unknown", described as "pain"; PARAPSORIASIS (non-serious) with onset 20Jul2021, outcome "unknown", described as "Pityriasis lichenoides chronica (PLC)"; RASH PAPULAR (non-serious) with onset 24Apr2021, outcome "unknown", described as "Papulovesicular". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of rash, rash pruritic, parapsoriasis, rash papular.  Additional Information: It was reported that patient Did not require medical intervention, was not hospitalized, was not visited Emergency department. No, the patient admitted to an intensive care unit. No, multiorgan involvement. It was reported that patient do not have a history of any previous allergies to specific products or any conditions indicative of an allergy. Did the event require the initiation of new medication or other treatment or procedure?: yes Details: oral and topical steroids; antihistamines. The patient did not received any other medications prior to the event, and the patient did not received any vaccines for any other conditions prior to the event. And the patient did not received any vaccines for SARS-COV2 other than Pfizer-BioNTech COVID-19 Vaccine prior to the event. And the patient did not received any other vaccines around the time of Pfizer-BioNTech COVID-19 Vaccine vaccination. The Pfizer product had a casual effect to the adverse event. Physician calling about an adverse reaction a 33 yo female patient of his had with the Pfizer covid vaccine and would like to speak with someone about it. The caller wanted to report an adverse event to the Pfizer covid 19 vaccine for a 33 year old female patient. The patient was otherwise healthy and no problems with the first dose, 2 weeks after the second dose generalized eruption, a rash all over her body, lasted a coupled of months and resolved with treatment.  This happened again a month later. A biopsy was performed the pathology was unusual, it came back PLC. The caller is a dermatologist. The caller will have to reach out to the patient to get the information about her vaccine. The event has resolved at this current time. It was extremely uncomfortable with sleepless nights, there was as significant amount of pruritis and pain at individual lesions. The caller would not classify this as medically significant but it was something the patient could live with but it effected her lifestyle. Vaccination Facility Type: Pharmacy, No emergency room, physician office. Caller was trying to find out that Pfizer will be providing constituents for allergy testing for people who have reactions to see if its an allergy to the constituents in the vaccine. Caller knows that Pfizer does not have this information and will reach back out in the future. Caller was a physician reporting an adverse reaction for a patient after her second dose of the Pfizer-Biotech Covid19 vaccine (Comirnaty). Patient was an otherwise healthy 33y/o female, who tolerated her first dose of the vaccine fine. Two weeks after her second dose was administered, she developed a generalized eruption that continued for a couple of months and subsided with treatment. Clarified that this rash was all over her body, not just at the injection site. Months later, the patient experienced a milder case of the same eruption. Biopsies were done, and the caller reports the pathology was very unusual and showed Pityriasis lichenoides chronica (PLC) which the caller reports can recur unprovoked. Caller was looking for any information we may have about the patient condition.  He was most concerned about how to proceed with booster doses in the future.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.